Verici Dx

About MyWebSite

Verici Dx plc develops and commercializes RNA signature-based immuno-diagnostic tests to assess and monitor patient response to organ transplantation, with a focus on kidney transplants. Leveraging artificial intelligence and next-generation sequencing, the company provides personalized risk profiles and actionable data to clinicians, supporting improved patient and graft outcomes. Its technology deciphers immune response and other biological signals to predict risk of injury, rejection, and graft failure from pre-transplant to late-stage care.